GlassScriptPhysician profile
Ginny Merryman
NPI 1023126760
$1,288.99
in general payments reported to CMS, 2019-2025
27 companies · $59.25 in 2025
The $59.25 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $68.15 · 2021: $205 · 2022: $301 · 2023: $376 · 2024: $94.21 · 2025: $59.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $159.65 | 2020-2025 | Slynd |
| Abbvie INC. | $117.23 | 2019-2023 | |
| Organon LLC | $109.10 | 2022-2024 | |
| Astellas Pharma US INC | $107.17 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $91.30 | 2022 | |
| Aspira Women'S Health INC | $81.75 | 2021 | |
| Shield Therapeutics INC | $79.71 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $67.72 | 2019-2021 | |
| Sage Therapeutics, LLC | $58.64 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $53.08 | 2019 | |
| Coopersurgical, INC. | $40.89 | 2019-2023 | Paragard T 380a |
| Millicent US INC | $37.13 | 2019-2023 | Femring, Intrarosa |
| Bayer Healthcare Pharmaceuticals INC. | $34.46 | 2022-2023 | |
| Pfizer INC. | $32.80 | 2019-2023 | |
| Hologic Sales and Service, LLC | $27.99 | 2023 | Aptima, Thinprep 2000 Processor |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dysis Medical, INC. | $27.17 | 2023 | Dysis View, Dysis Ultra 2.0, Dysis V3 Digital Coploscope |
| Exact Sciences Corporation | $22.40 | 2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $20.97 | 2021 | |
| Mylan Pharmaceuticals INC. | $20.44 | 2021 | |
| Agile Therapeutics, INC. | $17.06 | 2021 | |
| Horizon Therapeutics Plc | $16.65 | 2021 | |
| Mayne Pharma Commercial LLC | $14.85 | 2022 | |
| Sumitomo Pharma America, INC. | $14.63 | 2023 | Myfembree |
| Vertical Pharmaceuticals, LLC | $12.82 | 2019 | |
| Minerva Surgical, INC | $12.35 | 2021 | |
| Avion Pharmaceuticals | $11.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginny Merryman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.